Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Gallium-68 (Ga-68) DOTATATE is a radiolabeled peptide-imaging modality that targets the somatostatin receptor (SSTR), especially subtype 2 (SSTR2). Benign and malignant thyroid tumors have been observed to express SSTR. The aim of this study was to evaluate the frequency and clinical significance of incidental atypical thyroid uptake as detected by Ga-68 DOTATATE positron emission tomography/computed tomography (PET/CT).
Methods: A retrospective analysis was conducted of a prospective study in which 237 patients underwent Ga-68 DOTATATE PET/CT as part of a work-up for metastatic and unknown primary neuroendocrine tumors. The types of uptake in the thyroid gland (focal/diffuse) and maximum standardized uptake value (SUVmax) levels were evaluated and compared with the background uptake in the liver and salivary glands.
Results: Of 237 patients, 26 (11%) had atypical thyroid uptake as detected by Ga-68 DOTATATE PET/CT. There were no significant clinical or biochemical variables associated with atypical thyroid uptake. Fourteen (54%) patients had positive focal uptake, and 12 (46%) patients had diffuse uptake. Of the 14 patients with atypical focal uptake, 10 (71%) had thyroid nodules on the corresponding side, as detected by anatomic imaging. Three of 10 patients (21%) were found to have papillary thyroid cancer, and seven (70%) had adenomatoid nodules. Of the 12 patients with diffuse increased uptake, six (50%) had a history of hypothyroidism, five (42%) had chronic lymphocytic thyroiditis, and one (8%) had nontoxic multinodular goiter.
Conclusions: Patients with an incidental focal abnormal thyroid uptake on Ga-68 DOTATATE PET/CT scan should have further clinical evaluation to exclude a diagnosis of thyroid cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913484 | PMC |
| http://dx.doi.org/10.1089/thy.2016.0174 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
High risk factors, molecular features and clinical management for radioactive iodine-refractory differentiated thyroid carcinoma.
Front Oncol
August 2025
Department of Pathology, Institute of Clinical Pathology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Despite the generally favorable prognosis of differentiated thyroid carcinoma (DTC) following surgery and radioactive iodine (RAI) therapy, approximately 10% of cases eventually develop resistance to RAI. This condition, known as radioiodine-refractory differentiated thyroid carcinoma (RAIR-DTC), is associated with a poor prognosis, with a 10-year survival rate of only 10% from the time of metastasis detection. The limited availability of safe and effective alternative treatments poses a significant challenge to clinical management.
View Article and Find Full Text PDFA presentation of brown tumor in a patient with parathyroid adenoma and end-stage renal disease: A case report.
Medicine (Baltimore)
September 2025
Department of Internal Medicine, Lahore General Hospital, Lahore, Punjab, Pakistan.
Rationale: Brown tumor (osteitis fibrosa cystica) is a benign bone lesion associated with hyperparathyroidism that can affect multiple bones in patients with end-stage renal disease (ESRD).
Patient Concerns: We present the case of a 32-year-old female with ESRD on maintenance hemodialysis who experienced body aches, muscle weakness, constipation, and mood swings for 3 months.
Diagnoses: Initial tests revealed elevated parathyroid hormone (PTH), serum calcium, and phosphorus levels.
Pembrolizumab-Induced Retroperitoneal Fibrosis Detected on 68Ga-FAPi PET/CT.
Clin Nucl Med
September 2025
Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Hepatocellular carcinoma is one of the leading causes of cancer-related death worldwide. Immune checkpoint inhibitors (ICI) have improved progression and overall survival in patients progressing on sorafenib therapy. But activation of the immune system can lead to numerous immune-related adverse events.
View Article and Find Full Text PDFGlucose metabolism in anterior pituitary adenomas.
Clin Chim Acta
September 2025
Pain Management Center, Hospital Angeles Mocel, Mexico City, Mexico.
Glucose metabolism alterations are frequently observed in patients with secretory pituitary adenomas. The most commonly secreted hormones in these tumors include prolactin, growth hormone (GH), adrenocorticotropic hormone (ACTH), and thyroid-stimulating hormone (TSH), all of which can disrupt glucose homeostasis through distinct pathophysiological mechanisms. Prolactin stimulates pancreatic β-cell proliferation, enhances insulin gene transcription, increases intracellular insulin content, and augments glucose-induced insulin secretion.
View Article and Find Full Text PDFThyroid hormone promotes fetal neurogenesis.
JCI Insight
September 2025
Department of Internal Medicine, The University of Texas Medical Branch, Galveston, United States of America.
Maternal low thyroxine (T4) serum levels during the first trimester of pregnancy correlate with cerebral cortex volume and mental development of the progeny, but why neural cells during early fetal brain development are vulnerable to maternal T4 levels remains unknown. In this study, using iPSCs obtained from a boy with a loss-of-function mutation in MCT8-a transporter previously identified as critical for thyroid hormone uptake and action in neural cells-we demonstrate that thyroid hormones induce transcriptional changes that promote the progression of human neural precursor cells along the dorsal projection trajectory. Consistent with these findings, single-cell, spatial, and bulk transcriptomics from MCT8-deficient cerebral organoids and cultures of human neural precursor cells underscore the necessity for optimal thyroid hormone levels for these cells to differentiate into neurons.
View Article and Find Full Text PDF